F. Hoffmann-La Roche is a global health-care company providing a broad spectrum of innovative medical solutions, operating worldwide under two division: Pharmaceuticals & Diagnostics. Roche is the leading provider of cancer treatments globally.
- In Oct 2018, Roche acquired UK-based immuno-oncology company Tusk Therapeutics in a deal valued at up to €655 Mn ($759 Mn). Tusk Therapeutics’ pipeline consists of an anti-CD25 antibody program designed to reduce regulatory T-cells (Tregs), which suppress immune responses, even those against cancer cells.
- In Apr 2018, Roche acquired Foundation Medicine, a U.S.-based company makes molecular-diagnostic tests that identify alterations in a patient’s cancer for $2.4 Billion.
- In Dec 2017, Roche acquired Ignyta, Inc. (NASDAQ: RXDX) in US$ 1.7 billion and merged in itself. Ignyta’s lead molecule entrectinib is an orally bioavailable, CNS-active tyrosine kinase inhibitor being developed for tumors that harbor ROS1 or NTRK fusions.
- In Aug 2014, Roche acquired Santaris Pharma for up-to-$450 Mn, a privately held biopharma company focusing on the development of RNA-targeted therapies for various diseases with a proprietary Locked Nucleic Acid (LNA) platform.
- In July 2014, Genentech, a member of Roche Group, acquired Seragon Pharmaceuticals, Inc. in payment upto $1.7 billion USD.
- In Jul 2011, it acquired mtm laboratories AG, a privately-held company based in Germany, developing diagnostic tests for cancer for $269 Mn USD.
- In Mar 2009, Genentech Inc, a major American biotechnology company was acquired by Roche for approx. $100 billion USD. Genentech currently operates as a wholly owned subsidiary of Roche.
- In Apr 2008, Roche acquired Piramed Ltd, a privately-owned UK company in $175Mn USD, developing therapies targeting PI3-kinase.
- In Jul 2005, Roche acquired GLYCART Biotechnology AG, developing mAbs for cancer and autoimmune diseases, for $295.6 Mn USD and having Obinutuzumab/GA101 and RO5083945/GA201 in its developmental pipeline.
- In Oct 2002, Roche acquired 50.1% stake in Chugai Pharmaceuticals, a Japanese biotechnology company, currently operating as a member of Roche Group.
Page 1 of 3
